Literature DB >> 20932661

Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas.

Stephanie E Combs1, Daniela Schulz-Ertner, Jürgen Debus, Andreas von Deimling, Christian Hartmann.   

Abstract

PURPOSE: To evaluate the correlation between the 1993 and 2000/2007 World Health Organization (WHO) classification with the outcome in patients with high-grade meningiomas. PATIENTS AND METHODS: Between 1985 and 2004, 73 patients diagnosed with atypical or anaplastic meningiomas were treated with radiotherapy. Sections from the paraffin-embedded tumor material from 66 patients (90%) from 13 different pathology departments were re-evaluated according to the first revised WHO classification from 1993 and the revised classifications from 2000/2007. In 4 cases, the initial diagnosis meningioma was not reproducible (5%). Therefore, 62 patients with meningiomas were analyzed.
RESULTS: All 62 tumors were reclassified according to the 1993 and 2000/2007 WHO classification systems. Using the 1993 system, 7 patients were diagnosed with WHO grade I meningioma (11%), 23 with WHO grade II (37%), and 32 with WHO grade III meningioma (52%). After scoring using the 2000/2007 system, we found 17 WHO grade I meningiomas (27%), 32 WHO grade II meningiomas (52%), and 13 WHO grade III meningiomas (21%). According to the 1993 classification, the difference in overall survival was not statistically significant among the histologic subgroups (p=.96). Using the 2000/2007 WHO classifications, the difference in overall survival became significant (p=.02). Of the 62 reclassified patients 29 developed tumor progression (47%). No difference in progression-free survival was observed among the histologic subgroups (p=.44). After grading according to the 2000/2007 WHO classifications, significant differences in progression-free survival were observed among the three histologic groups (p=.005).
CONCLUSION: The new 2000/2007 WHO classification for meningiomas showed an improved correlation between the histologic grade and outcome. This classification therefore provides a useful basis to determine the postoperative indication for radiotherapy. According to our results, a comparison of the published data for future treatment decision-making remains difficult when the histologic diagnosis has not been based on the new improved classification system.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20932661     DOI: 10.1016/j.ijrobp.2010.07.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

2.  Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.

Authors:  Varun R Kshettry; Quinn T Ostrom; Carol Kruchko; Ossama Al-Mefty; Gene H Barnett; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

3.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

4.  Proton therapy for atypical meningiomas.

Authors:  Mark W McDonald; David A Plankenhorn; Kevin P McMullen; Mark A Henderson; Edward J Dropcho; Mitesh V Shah; Aaron A Cohen-Gadol
Journal:  J Neurooncol       Date:  2015-04-10       Impact factor: 4.130

5.  Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011.

Authors:  Ryan L Lym; Quinn T Ostrom; Carol Kruchko; Marta Couce; Daniel J Brat; David N Louis; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-04-12       Impact factor: 4.130

6.  Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age.

Authors:  Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-02       Impact factor: 4.553

7.  Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Authors:  C Leland Rogers; Arie Perry; Stephanie Pugh; Michael A Vogelbaum; David Brachman; William McMillan; Joseph Jenrette; Igor Barani; Dennis Shrieve; Andy Sloan; Joseph Bovi; Young Kwok; Stuart H Burri; Samuel T Chao; Aaron C Spalding; Mitchell S Anscher; Beatrice Bloom; Minesh Mehta
Journal:  Neuro Oncol       Date:  2015-10-22       Impact factor: 12.300

8.  Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.

Authors:  Ayal A Aizer; Nils D Arvold; Paul Catalano; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ossama Al-Mefty; Patrick Y Wen; David A Reardon; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Stephanie E Weiss; Shakti H Ramkissoon; Malak Abedalthagafi; Sandro Santagata; Ian F Dunn; Brian M Alexander
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

9.  High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.

Authors:  C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-29       Impact factor: 7.038

10.  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Authors:  Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; David Brachman; Joseph M Jenrette; John De Groot; Joseph A Bovi; Maria Werner-Wasik; Jonathan P S Knisely; Minesh P Mehta
Journal:  J Neurosurg       Date:  2017-10-06       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.